Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis, Bayer CropScience, Monsanto, and Cargill Launch Crop Genomics Project

NEW YORK, Dec. 23--Agrinomics, the joint venture between Exelixis and Crop Science, has launched a crop genomics collaboration with Renessen, the joint venture between Monsanto and Cargill, the companies announced on Dec. 19.


The two companies will partner to improve seed oil crops. Agrinomics will apply its functional genomics expertise, including gene screening and phenotypic identification. Renessen will direct development and commercialization.


In the deal, Agrinomics will receive research funding, pre-commercial milestone payments, and royalties on any commercialized products from Renessen. Renessen will also direct the development of transgenic strains.


Agrinomics, launched in 1999, has developed a gene discovery platform based on Arabidopsis gene expression.


Canola and soybeans are the major oil seed crops, accounting for more than 70 percent of the $32 billion global market, according to the companies.


For further information, see the statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.